Omicron variant to be detected in 20 minutes by molecular diagnosis test

Korean researchers have developed molecular diagnostics technology that can detect Omicron variants. The technology development has been currently completed, and it is expected to take time for commercialization.

POSTECH announced on the 10th that a research team led by Professor Lee Jung-wook of the Department of Chemical Engineering has developed molecular diagnostic technology that can detect the Omicron variant in just 20-30 minutes and will publish the results online.

Omicron is a variant in which 26-32 mutations in the spike, which is used to infect cells by the COVID-19 virus.

According to the research team, molecular diagnostics technology can distinguish mutations at the single-nucleotide base, so it can detect ‘Stealth Omicron,’ which are difficult to be detected by PCR tests.

Currently, the Korea Centers for Disease Control and Prevention is using three methods to detect COVID-19 variants: whole-genome analysis, target DNA (mutations such as spike protein) analysis, and PCR test.

In the case of the Delta variant, it can be detected by the current PCR test, but Omicron cannot.The newly developed technology this time is not a sequencing method that reads DNA or RNA sequences, but the molecular diagnostic technology.

The existing technology screens only specific areas of the virus, but the molecular diagnostic technology was designed to cause nucleic acid-binding reactions only when the COVID-19 RNA exists, enabling rapid detection.

According to Professor Lee, Omicron has a strong signal for N genes in PCR tests but has a weak signal for S genes. In the case of ‘Stealth Omicron,’ both N and S genes confirmed positive, making it difficult to distinguish from other variants. The molecular diagnostic technology works in different mechanisms from PCR, detecting the Omicron variant efficiently.

Unlike conventional technology that generally processes up to 96 samples per device, the new technology can process more than 125 in 30 minutes (more than 250 samples per hour). In addition, this technology does not need specialized equipment, thus can make diagnostic kits simply and easily.

As the method can develop the diagnosis kit in 4 days, it is expected to respond quickly even if a new variant or virus occurs in the future.

“I hope the disclosure of this technology will help us return to normal daily life as soon as possible,” said Professor Lee. “We will try to quickly diagnose and respond to new variants that may come out after COVID-19.”

This technology is currently before commercialization. However, it can be used as an auxiliary in current situations where the PCR test for Omicron has not been developed.

Professor Lee said, “I think this technology will be close to commercialization in the second half of next year after clinical trials. The reason why I disclose the technology is to share it with others to develop better technologies for overcoming COVID-19 and to allow underdeveloped countries also analyze COVID-19 variants.”

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India